In early clinical trials, tazemetostat, an EZH2 inhibitor that also reduces methyltransferase activity in EZH2 mutant and wild-type FL [81], produced CR rates of 38% in participants with NHL [82] and 33% in participants with R/R DLBCL [83]. The gene discussed is EZH2; the disease is non-Hodgkin lymphoma.